title: Estrogen effects on insulin-like growth factor gene expression in a human osteoblastic cell line with high levels of estrogen receptor.
abstract: Insulin-like growth factors (IGF)-I and IGF-II are produced by osteoblasts and are important paracrine/autocrine regulators of osteoblast proliferation and differentiation. Estrogen has been reported to increase gene expression of IGF-I in rodent osteoblasts. However, because species differences have been demonstrated in expression of various aspects of the IGF system in bone cells, it is not known whether this action also occurs in human osteoblasts. Thus, we assessed the effects of estrogen treatment on IGF-I and IGF-II gene expression in vitro in a recently developed human fetal osteoblast cell line that has high levels of estrogen receptors. As assessed by a quantitative reverse transcriptase-polymerase chain reaction method, treatment of hFOB/ER9 cells with 17beta-estradiol (E2) increased steady state levels of IGF-I mRNA in a time- and dose- dependent fashion with a maximal increase of 319% +/- 33% (P < 0.01) of control occurring after treatment with 10(-7) M E2 for 48 hours. In contrast, E2 did not alter steady state levels of IGF-II mRNA. The pure (type 2) antiestrogens ICI 182,780 (10(-7) M) and ICI 164,384 (10(-6) M) blocked the E2- induced increase in IGF-I mRNA levels. Interestingly, 4-hydroxytamoxifen (10(-7) M), a documented pure antiestrogen in reproductive tissues, also increased IGF-I mRNA to levels similar to those observed in E2-treated cells. Since E2 was shown to mediate its effects on some target genes through a cAMP-dependent pathway, we studied the interaction between E2 and agents that are known to increase intracellular cAMP. Forskolin (10(-8) M) and dibutyryl cAMP (10(-3) M) increased IGF-I mRNA levels sixfold, and cotreatment with E2 did not affect these changes, consistent with a possible mediation of the estrogen effect on IGF-I gene expression by cAMP. We conclude that in human osteoblastic cells, the IGF-I gene is a target for estrogen action, suggesting that IGF-I may mediate part of the effects of estrogen in human bone.
authors.affiliation: Endocrine Research Unit, Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, North 6 Plummer, Rochester, Minnesota 55905, USA.
authors.forename: M
authors.initials: M
authors.lastname: Kassem
authors.forename: R
authors.initials: R
authors.lastname: Okazaki
authors.forename: S A
authors.initials: SA
authors.lastname: Harris
authors.forename: T C
authors.initials: TC
authors.lastname: Spelsberg
authors.forename: C A
authors.initials: CA
authors.lastname: Conover
authors.forename: B L
authors.initials: BL
authors.lastname: Riggs
mesh_terms: D003994:Bucladesine / Q000494:pharmacology; D002460:Cell Line; D005576:Colforsin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology*; D000077267:Fulvestrant; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000187:drug effects* / Q000235:genetics*; D007335:Insulin-Like Growth Factor II / Q000187:drug effects / Q000235:genetics; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D016133:Polymerase Chain Reaction; D053284:Polyunsaturated Alkamides; D045167:Progesterone Congeners / Q000494:pharmacology; D011397:Promegestone / Q000494:pharmacology; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D011960:Receptors, Estrogen / Q000819:agonists / Q000187:drug effects* / Q000378:metabolism; D012680:Sensitivity and Specificity; D013997:Time Factors; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D004965:Estrogen Antagonists; D004967:Estrogens; D053284:Polyunsaturated Alkamides; D045167:Progesterone Congeners; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D005576:Colforsin; D000077267:Fulvestrant; D004958:Estradiol; D003994:Bucladesine; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; C051781:ICI 164384; D011397:Promegestone; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases